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Abstract
MicroRNAs (miRNAs) in body fluids are candidate diagnostics for a variety of conditions and diseases, including breast
cancer. One premise for using extracellular miRNAs to diagnose disease is the notion that the abundance of the miRNAs in
body fluids reflects their abundance in the abnormal cells causing the disease. As a result, the search for such diagnostics in
body fluids has focused on miRNAs that are abundant in the cells of origin. Here we report that released miRNAs do not
necessarily reflect the abundance of miRNA in the cell of origin. We find that release of miRNAs from cells into blood, milk
and ductal fluids is selective and that the selection of released miRNAs may correlate with malignancy. In particular, the bulk
of miR-451 and miR-1246 produced by malignant mammary epithelial cells was released, but the majority of these miRNAs
produced by non-malignant mammary epithelial cells was retained. Our findings suggest the existence of a cellular
selection mechanism for miRNA release and indicate that the extracellular and cellular miRNA profiles differ. This selective
release of miRNAs is an important consideration for the identification of circulating miRNAs as biomarkers of disease.
Citation: Pigati L, Yaddanapudi SCS, Iyengar R, Kim D-J, Hearn SA, et al. (2010) Selective Release of MicroRNA Species from Normal and Malignant Mammary
Epithelial Cells. PLoS ONE 5(10): e13515. doi:10.1371/journal.pone.0013515
Editor: Gordon Langsley, INSERM U1016, Institut Cochin, France
Received June 2, 2010; Accepted September 14, 2010; Published October 20, 2010
Copyright:  2010 Pigati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the United States Department of Defense grant W81XWH-08-1-0641, and an American Cancer Society of Illinois Research
Grant 08–29 to DMD, Rosalind Franklin University of Medicine and Science start-up funds and support of the Bligh Cancer Research Center. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We acknowledge the Midwest Proteome Center, funded
by NIH NCRR S10 RR19325, and HRSA C76 HF03610-01-00 for services rendered.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Dominik.Duelli@Rosalindfranklin.edu
¤ Current address: Radiation and Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri,
United States of America
Introduction
MicroRNAs (miRNAs) are small RNAmolecules that are defined
by structure, regulatory functions, and mode of biogenesis. In a
canonical pathway, miRNAs are produced as primary miRNA
transcripts (pri-miRNA), which are processed by the Microproces-
sor complex that includes Drosha into pre-miRNA molecules. Pre-
miRNAs are exported from the nucleus, and further processed by
Dicer to yield mature miRNAs that associate with the RNA-
Induced Silencing Complex, RISC and target mRNA. Changes in
the abundance of miRNAs have been documented in various
diseases including malignancies such as breast cancer. The cellular
miRNA composition has been explored for diagnosis and prognosis
of breast cancer and other diseases [1,2,3,4,5,6,7,8,9,10]. Because
upregulated miRNAs of lymphoma, prostate, lung and breast
cancers have also been detected in blood plasma and serum
[11,12,13,14], circulating miRNAs are currently evaluated as
surrogate biomarkers for breast cancer [14,15,16,17], other cancers
[13,18,19,20], diseases or conditions [21].
Cells in culture and in the body release a variety of nucleic acids
into the environment, including cellular and viral mRNAs and
miRNAs. At least some of these RNAs have been found to be
encapsulated in micro- and nano-vesicles released from cells
[22,23,24,25,26,27,28]. One such vesicle is the exosome, which
originates from multivesicular bodies (MVB), and is released by
cells in the body and in culture [23,24,25,27,29]. For ovarian and
lung cancer and glioblastoma, circulating miRNAs have been
found present in exosome-like vesicles [19,20,30].
While mechanisms that control the release of viral RNA have been
studied extensively, the mechanism of miRNA release is not clearly
understood. Recent data suggest that miRNA release may occur
through a ceramide-dependent secretory machinery [31]. In
addition, mature miRNAs have been reported to be released from
cells in exosomes as a consequence of the MVB’s role in loading
miRNAs to their complementary target mRNA in the RNA-Induced
Silencing Complex, RISC [32]. However, immature miRNAs are
also released [29] and apoptotic bodies are thought to contain
miRNA [33], suggesting alternative mechanisms of miRNA release.
Blood contains vesicular miRNA of many cells, which may
make it necessary to enrich organ, tissue, or cell-type-specific
exosomes using surface markers for proper quantitation
[19,20,34]. However, in addition to releasing miRNAs into blood,
mammary epithelia produce and condition specialized body fluids,
including mammary fluid in the resting gland, and milk during
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lactation. Thus, mammary fluids might provide an alternate body
fluid to measure diagnostic miRNAs of extracellular human
mammary epithelial cell (HMEC) for breast disease.
For identification of circulating diagnostic miRNAs, most
approaches thus far have focused on quantifying circulating
miRNAs that are overexpressed or lost in the cancer cell of origin
[13,18,30,35]. However, only some of the highly abundant cellular
miRNAs have been found in higher concentrations in circulation,
suggesting that only a subset of cellular miRNAs are released into
the environment [29]. These findings prompted us to test whether
cells release different miRNAs than they retain. We found that
nearly 30% of the released miRNAs in vitro and in vivo do not reflect
the cellular profile, suggesting that some miRNAs are retained or
released selectively. Some selectively released miRNAs were
enriched in body fluids conditioned by mammary cells, including
mammary fluids, blood and milk. This subset of miRNAs may have
value in breast cancer diagnosis and biology. Our results stress that
miRNAs are released selectively, and that extracellular miRNAs
should be considered independent of cellular miRNAs abundance
when considering diagnostic markers of disease.
Results
Mammary epithelial cells release exosomal vesicles with a
distinct small RNA profile
To compare intracellular and extracellular miRNA populations,
we analyzed the breast cancer cell line MCF7, which releases
exosomes [36]. We focused on RNA contained in vesicles, because
such vesicles are released from cells in vitro, as well as into blood,
urine, saliva and other body fluids [14,15,19,20,23,24,25,27,30,37].
We enriched for vesicles by centrifugation at 70,000 g from media
conditioned by MCF7 cells (Figure 1). This preparation (P70)
included cup-shaped vesicles of about 100 nm (Figure 1A), which
is consistent with exosomes; and was enriched in CD81, a marker
protein of exosomes (Figure 1B).
To assess if other human mammary epithelial cells release
exosomes, we quantified the abundance of CD81 and CD63, an
endosomal marker protein, in P70 preparations of breast cancer
cell lines MDA-MB-231, BT-20, and the nontumorigenic
mammary epithelial cell line MCF 10A. We found that P70
preparations of all cell lines contained CD63 and CD81 at similar
Figure 1. Differential Cellular Release and Retention of Small RNAs.Medium conditioned by MCF7 cells for 5 days was enriched for exosomes by
a filtration and ultracentrifugation protocol producing a P70 preparation. A The P70 was subjected to negative-staining EM. B The abundance of
tetraspanin CD81, an exosome-marker was assessed in the filtered conditioned medium, the P70 pellet obtained by ultracentrifugation, and the
supernatant (S70) using slot-blot (inset, n = 2). C The surface antigens CD81, CD63 and Mucin-1 were detected in the P70 fraction of the mammary
epithelial cells using slot-blot. The absolute amount of bound antibody was quantified using standard-curves of antibody dilutions, and expressed as a
percent of total antigenicity for the P70 of each cell line. The data of two replicate experiments for the indicated cell lines are shown.D Radiolabeled small
RNAs isolated fromMCF7 cells (c) and the extracellular preparation P70 (x) were separated by PAGE on a 12% denaturing gel. Star: Extracellular enriched
RNA; Circle: Some extracellular RNAs identified by sequencing (see text and Tables S1 and S2). E Quantitation of labeled RNA species of D. The thin line
indicates abundance of cellular small RNAs, whereas the thick line indicates the abundance of the extracellular miRNAs.
doi:10.1371/journal.pone.0013515.g001
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proportions as MCF7 cells (Figure 1C), suggesting that mammary
epithelial cells in general release similar vesicles.
We also tested for the presence of the epithelial-cell marker
Mucin-1 and other antigens on vesicles released from mammary
epithelial cells (Figures 1C). We found several proteins with roles
in mammary biology present in similar abundance, leading us to
conclude that vesicles of mammary epithelial cells share antigenic
properties.
To compare the cellular to the extracellular small RNA population,
we collected total RNA of MCF7 cells or media conditioned by these
cells after 5-days of culturing. We then radiolabeled small RNAs
enriched from MCF7 cells (c) and P70 (x) and analyzed their
migration by polyacrylamide gel electrophoresis (PAGE) and
autoradiography (Figures 1D and 1E).
We found that the majority of small RNAs migrated differently
in extracellular than intracellular preparations, indicating that the
released and retained RNA populations were not the same.
Furthermore, the extracellular fraction included some RNA
species that were less abundant in the cell. For example, in one
band that is highly enriched in the P70, we identified by
sequencing, RNAs that are cleavage products of 5.8S rRNA and
a U1 small nuclear RNA (Figure 1E, and Table S1A and S1B),
whereas common RNAs of a region with a similar banding pattern
in cellular and extracellular preparations contained 28S rRNA
fragments (Table S2). Therefore the extracellular RNA popula-
tion is enriched in some RNA species underrepresented in the cell.
Extracellular and cellular miRNA populations are different
Because of the suggested roles of extracellular miRNAs in
signaling and diagnosis [27], we investigated whether the
intracellular and extracellular miRNA composition are the same.
To answer this question, we performed microRNA microarray
analyses of MCF7 cellular (c) and extracellular (x) RNAs
(Figure 2A), and found that about 66% of the released miRNAs
are at an abundance that closely reflects the cellular miRNA
abundance (Figures 2B and 2C). This finding is in agreement
with a model wherein most, but not all miRNAs are released
passively by mass action.
To confirm the miRNA composition determined by microarray
hybridization, we measured the cellular and extracellular mature
miRNA populations by quantitative PCR approaches after
reverse-transcription of miRNAs (qRT-PCR). We used two
approaches that are specific for mature human miRNAs: 39
linkering as modified from [38], and stem-loop primers [39]
(Tables S3 and S4). We first focused on miRNAs that were
reported to be involved in mammary and cancer biology or cancer
diagnostics [1,6,7,15,40,41,42,43,44,45,46] (Figure 2D and E).
We verified the identity of many species by sequencing (Table
S5). The quantified miRNAs were normalized to a synthetic RNA
(INT-RNA) to control for RNA recovery (Table S4 and Materials
and Methods).
Absolute quantitation of miRNAs allowed us to determine that
only a small portion of the cellular pool of most miRNA species is
released. In particular, only about 2% of the most abundant
miRNA, miR-720 was released into the environment within 5 days
of culturing (Figure 2D, and data not shown). Importantly, we
confirmed that many miRNAs were represented at comparable
proportions in the cellular and extracellular population (e.g. miR-
638), whereas several other miRNA species were overrepresented
either of these populations (e.g. miR-451 and miR-107)
(Figure 2D). These data suggest that cells have a mechanism in
place to select some miRNAs for cellular release or retention.
Therefore, we investigated the selective nature of miRNA release
further.
miR-16 is a surrogate marker of bulk exosome release
Because the transformation status of a cell regulates exosome
secretion [47], and thus possibly exosomal miRNA release, we
sought to identify a miRNA that faithfully reflects exosomal
abundance in order to quantify selective miRNA release into
vesicles. For example, miR-103 and its paralog miR-107 have high
and consistent expression in both cancerous and normal
mammary tissues, and thus have been used for normalizing
miRNA studies comparing mammary cells [42]. However, these
miRNAs were grossly underrepresented in the extracellular
fraction (Figures 2 A and B), highlighting the observation that
at least some miRNAs with diagnostic value in cells are not
represented in the released population. We therefore considered
other miRNAs for normalization. Using the more sensitive stem-
loop primer PCR approach [39], we focused on several miRNAs,
including the most abundantly released miRNA of MCF7 cells,
miR-720; miR-21; miR-16; and microRNAs that were enriched
extracellularly, including miR-451, miR-1275 (Figure 3A). We
measured the cellular to extracellular ratio of these miRNAs in a
set of HMECs including cell lines BT-20, MCF 10A, MCF7,
MDA-MB-231, and SK-BR-3. We found that HMECs irrespec-
tive of malignancy, released a constant amount of miR-21
reflective of cellular abundance, a miRNA that is upregulated in
many breast cancers [6,7,8], and miR-16 (Figure 3A). The most
consistently released miRNA was miR-16 of which for each
released molecule, 160–400 molecules were retained.
We tested whether exosome release correlated with miR-16
release, and found that the abundance of extracellular miR-16
correlated with the amount of microvesicular marker protein
CD81 released from cells (Figure 3B). This observation suggested
that miR-16 is not subject to a selection mechanism beyond
packaging into exosomes.
The consistency of release, and the fact that miRNA-16 is
known to have relatively high and stable expression in both
normal and transformed breast tissue [48], led us to conclude that
extracellular miR-16 is a surrogate marker for the abundance of
vesicular miRNAs. Using miR-16 as an internal standard, we
addressed the observed differences in the release rate of specific
miRNAs.
Extracellular miRNA accumulation is linear
We measured properties of extracellular miRNAs, including
their release rate and stability. To do so, we focused on miR-16,
miR-1246, miR-451 and miR-720. We found that individual
miRNAs were released at different rates. MiR-16 accumulated the
slowest, with less than a doubling of the extracellular miRNA
concentration per day. In contrast, the extracellular accumulation
of miR-1246 more than doubled per day (Figure 3C). These rates
were also different among cell lines. For example the rate of
accumulation of miR-720 was about 17 times higher in MCF7
cells than MCF 10A cells (Figure 3C). However, we found that
the concentrations of these miRNAs dropped no more than 2-fold
upon storage of P70 for up to 3 days, the maximum time we
measured (data not shown), suggesting that stability alone cannot
account for the differences in extracellular miRNA levels. These
findings fit with a model wherein miRNAs are released at a
constant and miRNA-species specific rate.
Some diagnostic miRNAs are selectively retained by cells
Our array analyses indicated that 13% of the MCF7 miRNA
species were selectively retained by the cell. This category included
miR-141, which was nearly undetectable in the released
population (Figures 2A and 2B), and which has roles in
carcinogenesis [49]. In contrast, miR-141 is abundantly released
Selective Release of MicroRNAs
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from other malignancies, including ovarian [50] and prostate
cancer cells [13,19]. Therefore, retention of some miRNAs is cell-
type specific.
To test whether the retention of other miRNAs was cell-type
and miRNA specific, we quantified the release of miR-27b, miR-
30c, and miR-23a from several cell lines using qRT-PCR. We
found that for these miRNA species, for each 100 molecules
produced, 0.5–20 molecules were released by most but not all
breast cancer cell lines tested (Figures 2A, 2D 3A and Figure 4).
This suggests, that in general, the retention of specific miRNAs is a
common phenomenon for breast cancer cells.
We tested if miRNAs with established roles in mammary
biology were also selectively retained by cells. We tested let-7c,
with roles in Myc regulation (reviewed in [45]) and in HMEC
progenitor cells [51]; miR-99a, which clusters with let-7c, and
resides in a commonly deleted chromosome region of lung [52]
and primary breast cancer [53]; miR-196a1, which is overex-
pressed in breast cancer cells [54], miR-210, a hypoxia sensor with
prognostic value in breast cancer [1,54,55]; miR-200b, a regulator
of epithelial-mesenchymal transition (EMT), [41,56,57]; and
several miRNAs associated with metastasis, miR-148a [58],
miR-335[5], miR-373 and miR-520c [3]). We found all of these
miRNAs in the MCF7 cellular component, yet we detected none
(Figure S1A) or very few (Figure S1B) of these miRNAs in the
extracellular population. Another miRNA, miR-1275, ranged
from 5-fold higher retention in MDA-MB-231 cells to 3-fold
enrichment in the spent media of MCF 10A, BT-20, and SK-BR-3
cells (Figures 2D, Figure 3, and Figures 4A and 4B).
Therefore miR-1275 release did not correlate with the transfor-
mation status of its cell of origin. Our findings that some miRNAs
Figure 2. Some MicroRNAs are Released Disproportionately. Duplicate microRNA microarrays were hybridized with 1 mg of total cellular or
1 mg of extracellular miRNA from MCF7 cells. Results are plotted as A relative fluorescent intensities of extracellular (x, upper panel) and cellular (c,
lower panel) miRNAs, or B ratio of extracellular to cellular miRNAs. The horizontal lines in B indicate the threshold of 2 fold-changes, whereas the red
and the green marked populations indicate a greater than 4-fold enrichment in the released extracellular (A, upper panel, x), or in the cells (A, lower
panel, c) respectively. C Scatter plot of average reads of the miRNAs quantitated by array. Only miRNAs with a fluorescent value of greater than 500 in
the cellular or extracellular population are shown (see Materials and Methods). The numbers next to dots indicate the miRNA the dot represents. D
MCF7 cells were cultured for 5 days, and the total amount of specific cellular and extracellular miRNAs were measured by quantitative linker-ligation
mediated RT-PCR, and the miRNA ratios were plotted. The average of 3 independent experiments is shown. E Native PAGE of products at end-point
of quantitative RT-PCR. The major PCR-products between 32–48 ntds correspond to the mature miRNA (miRNA) as expected by size and determined
by sequencing (Table S5). The bands with a migration of less then 25 ntds are the PCR primers (primers) used in the reaction. Bands that retained in
the well are amplification-independent reaction components (reaction components). Hsa-miR-923 has since been reclassified as a specific rRNA
fragment.
doi:10.1371/journal.pone.0013515.g002
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were underrepresented in the extracellular population might
explain reports in which increased plasma and serum levels of
some cancer-associated miRNAs, including oncogenic miR-155,
or miR-21 [1,54], could not be found in all breast cancer patients
[15,17]. Furthermore, this finding raises the possibility that cells
have mechanisms in place that retain miRNAs with roles in
carcinoma growth [59], cell differentiation [43,60,61] and
metabolism [62].
Selective release of immature miRNAs
Some [32,63], but probably not all [29] miRNAs are released as
a consequence of MVB’s function in loading miRNAs to their
target complementary mRNA by the RISC complex. Therefore,
we tested if immature miRNAs, which are not expected to
associate with RISC are also selectively released into the
extracellular space. We assessed several pre-miRNA species,
including precursors of preferentially released mature miRNAs
(miR-1246, miR-1275, mir-451, miR-638), selectively retained
miRNAs (let-7c, let-7f, let-7g, miR-100, miR-23a, miR-27, miR-
30c)), and precursors of miRNAs with biological and diagnostic
value in breast cancer (miR-155, miR-16, miR-21, miR-200c,
miR-221, miR-222) [64,65]. We quantified the released to
retained ratio using primers described in the section Materials
and Methods and in Table S6. Interestingly, precursors of mature
miRNAs that are preferentially released into the extracellular
space, including mir-451, miR-1275, miR-1246 were present only
in the cellular compartment (Figure 5A), confirming that the
measured extracellular miRNA is of the mature form only.
However, precursors of mature miRNAs that were nearly
exclusively detected in the cell, such as let-7c and miR-100, were
also detected only in the cells. Furthermore, immature oncomiR
miR-155, of which we could not detect the mature form
(Figure 2A, and data not shown) was also sequestered in cells
(Figure 5A). All other miRNAs were detected both in the cellular
as well as in the extracellular compartment (Figure 5B).
Furthermore, we detected no correlation between miRNA clusters
and the extent of release of their corresponding mature miRNAs
(Figure S2), suggesting that the release of mature and immature
miRNAs is regulated separately.
Quantitation of some miRNAs indicated that in every case
tested, more pre-miRNA molecules were retained than released
(Figure 5C). Recently two pre-miRNAs were also shown to be
released from human mesenchymal stem cells [29], suggesting that
the release of pre-miRNAs is not limited to MCF7 cells. In an
attempt to explain differences in release rates of immature
miRNAs, we sequenced some pre-miRNAs to test for modifica-
tions including RNA editing [66], yet found none (Table S7).
Therefore, selection mechanisms also exist for the release of pre-
miRNAs, however the nature of this process remains to be
established.
A caveat of the quantitation approach used in these studies, is
that it does not distinguish primary-miRNA transcripts (pri-
miRNAs) from pre-miRNAs [39]. To clarify, we probed for the
presence of sequences 59 of the Drosha processing sites [67]
(Figure 5D). We focused on 6 miRNAs, miR-200c, let-7c, miR-
221, miR-21, miR-23, miR-27 that were released to different
extents (Figure 2D). We found that the transcripts of 5 of these 6
miRNAs did not extend 59 of the Drosha-cut site (Figure 5D, and
data not shown), confirming that we measured bona fide pre-
miRNAs for these species, and that these miRNAs are released as
pre- but not as pri-miRNAs.
However, the transcript containing miR-200c extended 59 of
the stem-loop, as determined by PCR and sequencing (Figure 5D
and Table S7). We tested for pri-miRNA editing, which may
explain lack of processing [68,69] or release, yet found none in the
cellular or extracellular population (Table S7). These findings
suggest that in addition to releasing mature and pre-miRNAs, cells
also released miRNA transcripts that were not properly processed
either by Drosha or Dicer, including a miRNA locus relevant to
breast- and other cancers [40,70]. The finding of both pre-
miRNAs and longer transcripts supports the notion that miRNA
transcripts are released in ways in addition to, and independent of
those described as a consequence of RISC loading.
Breast cancer cells release most of their miR-451 and
miR-1246 molecules
Some miRNA species were 4 to 34-fold enriched in the
extracellular population (Figure 2). Interestingly, the absolute
concentration of several such species was greater in the
extracellular than the intracellular space (Figures 2A, 2B and
3A). We considered whether this enriched population was merely
overrepresented in the environment, because they constituted the
Figure 3. Extracellular miR-16 Levels Correlate with Nanovesicle Abundance. A Plot of extracellular to intracellular levels of miRNAs
quantitated by qRT-PCR using stem-loop primers of cells lines BT-20, MCF 10A, MCF7, MDA-MB-231 and SK-BR-3. MiRNA levels were calculated using
standard curves, and corrected for recovery by normalization to a spiked synthetic RNA (INT-RNA) introduced at the time of RNA-extraction (Materials
and Methods and Table S4). Error bars indicate the measure of one standard deviation of 3 independent experiments. B Relative levels of miR-16 and
absolute levels of CD81 were measured in P70 fractions of seven independent experiments and plotted. The line indicates a best-fit power curve
(r2 = 0.95). C The P70 was collected daily from media conditioned by MCF7 cells (solid symbols), or from MCF 10A cells (open symbol) cultures and
miRNAs were quantified in triplicate. The release rates were linear; r2 = 0.79 for miR-1246 (inset), r2 = 0.98 for miR-16, r2 = 0.85 for miR-451; and r2 = 0.87
for miR-720 of MCF7 cells.
doi:10.1371/journal.pone.0013515.g003
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most abundant cellular miRNA component. However, none of the
most abundant cellular miRNAs clustered into this category
(Figure 2B, lower panel). Therefore, properties other than
cellular miRNA abundance were responsible for the extent of
release of this miRNA subpopulation.
One of the most disproportionately released miRNAs was miR-
451, of which more than 90% of the total mature microRNA
population was exported into the extracellular space (Figures 2,
3, 4). MiR-451 is interesting, because it has been associated with
development, maintenance [71,72], and polarity [73] of epithelial
cells. In cancer, miR-451 has been reported to down-regulate
macrophage migration inhibitory factor, MIF [74], and multi-drug
resistance 1, MDR1 [75], and consequently rendering MCF7 cells
more sensitive to the chemotherapeutic agent doxorubicin [76].
We tested if preferential release of miR-1246 and miR-451 was
common in breast cancer cell lines, using miR-16 as an internal
control. We found that miR-451 and miR-1246 were selectively
released from four breast cancer cell lines tested, whereas the
release of these miRNAs from nontumorigenic MCF10A cells and
unrelated normal fibroblast cell line IMR90 was much lower
(Figure 4). In addition, the release rate of miR-451 was uniform
for MCF7 cells (Figure 3C), and accumulation of miR-451 was
relatively constant among the four cancer cell lines tested
(Figure 4A–4C). These data indicate that the release of the
majority of miR-451 into the medium is cell-type specific, and
perhaps more common in breast cancer cells. These results fit with
other studies in which miR-451 was barely detected in MCF7 cells
[76,77]. More importantly, the excessive release of miR-451 might
also provide a mechanism to explain how miR-451 accumulates
interstitially in breast cancer tumors [77]. Most notably, these data
suggest that cells produce some miRNA molecules of which more
are released into the environment than are retained.
We assessed if xenografted MCF7 and MDA-MB-231 cells also
release miRNAs into the murine blood circulation (Figure S3).
To do so, we normalized the measured miRNA levels to miR-22, a
miRNA that we did not find to be released from breast cancer
cells, but which was present in mouse blood. We found that
xenografting either cell line resulted in an increase in plasma levels
of miR-451, miR-720, miR-99a (Figure 6A). In addition, plasma
of mice injected with MCF7 cells, but not plasma of uninjected
littermates had detectable amounts of miR-1246 (Figure S3).
Therefore we conclude that breast cancer cell lines release
signature miR-451 and miR-1246 into the blood.
Ductal fluids contain extracellular miRNA signatures of
mammary epithelia
To test whether mammary epithelial cells also release the
identified signature miRNAs miR-451, miR-1246, miR-720, and
miR-16 in the human body, we focused on fluids that are heavily
conditioned by these cells; human milk, which has been reported
to contain exosomes [78] and miRNAs [79], and ductal lavages.
Figure 4. miR-451 and miR-1246 are Selectively Released from Cells. A The ratio of released to retained miRNAs standardized to released
and retained levels of miR-16 respectively, was quantified from the indicated cell lines using the linker-ligation qRT-PCR approach. B Native PAGE of
products at end-point of quantitative RT-PCR of indicated miRNAs using the stem-loop primer approach, and quantified in C. The major PCR-
products, indicated by arrows, correspond to the mature miRNA as expected by size (53 ntds for miR-1246, 53 ntds for miR-23a, and 56 ntds for miR-
451) and determined by sequencing (Table S5). The bands with a migration of less then 15 ntds are the PCR primers used in the reaction. The
stained material in the well is amplification-independent material of the reaction kit. The minor bands larger than 60 ntds represent artifactual
products amplified at low template concentration (Figure S5). All miRNAs were quantified from at least 3 cell and media collections, except for miR-
23a, which was measured only twice. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0013515.g004
Selective Release of MicroRNAs
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We found that lavages contained several miRNAs that we found to
be abundantly released from HMECs into culture media
(Figure 6B). Of these, the concentrations of miR-1246, miR-
451 and miR-720, normalized to miR-16 in the tested lavages and
milk were highly reminiscent of the extracellular miRNA
signature, but dissimilar to the intracellular HMEC miRNA
signatures (Figures 6B). Therefore, we conclude that both
mammary fluids contain extracellular miRNA species originating
from mammary epithelial cells in a specific conserved ratio.
We also detected differences in the miRNA signatures between
milk and lavages. For example, we detected a linear, constant ratio of
miR-16-normalized miR-451 to miR-1246 in both milk and lavages,
suggesting coordinated release of these two miRNAs. However, the
ratios of miR-451 and miR-1246 to miR-16 was much higher in the
lavages than the milk, suggesting an overall greater release of these
two miRNAs in the lavages compared to the milk (Figure 6B).
Perhaps, this difference reflects fluid origin. However, the ductal
lavages originate from donors that had epithelial atypia (lavages B
and C), and atypical ductal hyperplasia (ADH) on biopsy (lavage A,
[80]), whereas the milk was from normal donors. This difference
raises the possibility that increased miR-451 and miR-1246
concentrations are indicative of the presence of abnormal cells in
the mammary gland. In addition, the lavages of the patient with
ADH differed in the relative abundance of other miRNAs when
compared to the lavages with less severe epithelial atypia (Figure 6C),
perhaps indicating that different cellular changes induce different
modifications in the miRNA composition of ductal lavages.
Discussion
We report here that cells preferentially release and retain
miRNA subpopulations. These results are important when
considering circulating miRNAs for diagnosis, and in assessing
the biological significance of released miRNAs. For example, the
finding that transformed and malignant mammary epithelial cells
release most of their miR-451 into the environment has several
Figure 5. Immature miRNAs are Released at miRNA-Species Specific Rates. A and B, pre-miRNAs of MCF7 cells (c), and miRNAs released
from these cells (x) were amplified by rt-PCR and subjected to native PAGE. All the main bands correspond to the expected size of the amplification
products of immature miRNAs (arrowheads). Some of the amplification products were confirmed by sequencing (Table S7). C Those miRNAs that
yielded single bands in 3 independent experiments were quantified by qRT-PCR. D Presence of upstream RNA sequences, corresponding to pri-
miRNA sequences (Pri-s and Pri-l), and RNA corresponding to pre-miRNAs (Pre) were assed by PCR. The identity of the major products was confirmed
by sequencing (Table S7). Ntds: nucleotide size of sizing marker.
doi:10.1371/journal.pone.0013515.g005
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implications. Interestingly, miR-451 abundance has been reported
to correlate with breast cancer in tissue sections. However, miR-
451 was low in mammary epithelia, but enriched interstitially [77].
Therefore, miR-451 abundance was attributed to alternate origins,
and hence the usefulness of miR-451 in diagnosis was rejected.
Yet, miR-451 may have roles in breast- and other cancers
[46,74,81], and maps to an amplicon that includes HER2 and
BRCA1, which are commonly amplified in breast- and other
cancers [82,83,84]. Therefore, our finding that miR-451 is
selectively released from malignant mammary epithelial cells in
culture and in the body may be of importance for diagnostics.
In addition, we and others have described that viral RNAs and
proteins transferred in exosomes have biological functions relevant
to cancer ([23] and reviewed in [26,85,86]). In addition vesicular
miRNAs have been found to have signaling capacity [27,30].
Therefore, the finding that some miRNAs are released more
abundantly than retained may suggest a role of these miRNAs in
signaling. Perhaps selectively released miRNAs, including miR-
451 may be involved in paracrine signaling of the cancer and the
stroma [87], and in field cancerisation [88].
Alternatively, the release of miRNAs in exosomes might fit with
a trash disposal mechanism [89], in which cells release damaged
and other cellular components into the environment akin to a
house-cleaning mechanism. In agreement with this idea, we have
found the accumulation of specific rRNA and snRNA fragments,
and improperly processed miRNAs in the extracellular space.
However, because specific tRNA fragments have been found to
have distinct biological roles [90], RNA fragments may possibly be
more than degradation products destined for disposal.
The mechanism of selective miRNA release remains to be
determined. For example, in addition to an MVB-mediated
miRNAs release mechanism, cell death may be a mechanism of
miRNA release [17,33]. We considered this possibility, and found
that IMR90 cells and MDA-MB-231 cells in culture had similar
proportions of dead cells (11% and 9% respectively), yet MDA-
MB-231 cells released about 2.3 times more of their miR-16
molecules than IMR90 cells did (Figure 3A, and data not shown).
Therefore, cell death alone cannot explain the accumulation of
extracellular miRNAs. To identify the selection mechanism, it may
be informative to determine if the selective release and retention of
miRNA subpopulations is regulated by environmental cues. In
addition, the recent findings that miR-451 biogenesis is dicer-
independent [91], raise the possibility that miRNAs processed in
noncanonical ways may be specifically targeted for release through
mechanisms yet to be determined.
Our finding that the extracellular miRNA profile of ductal fluids
and HMECs is similar has several consequences. For example, it
opens the possibility of using the extracellular miRNA population
of ductal lavages for diagnosis, as is considered for proteins ([92]
and reviewed in [93,94]). This may be especially useful for women
at high-risk of breast cancer, where measurements of the
extracellular miRNA composition might supplement other
approaches, and overcome some of the diagnostic limitations of
analyzing the cellular composition of lavages [95,96]. In addition,
the finding of differences in the extracellular miRNA composition
of ductal fluids raises an interesting possibility that specific
miRNAs contribute to the multifunctional roles milk may have
during nursing [79] or consuming animal milk [97], and the
function ductal fluid miRNAs may have in the resting gland [98].
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The samples were collected under
NH/NCI Clinical Protocol # 02-C-0077. The study was
approved by the Institutional Review Board of RFUMS (IRB
protocol numbers # 001 PATH, # 002 PATH, and # 003
PATH). All patients provided written informed consent for the
collection of samples and subsequent analysis.
Figure 6. Extracellular Mammary Epithelial Signature miRNAs are Present in Body Fluids. A. Abundance of indicated miRNAs quantitated
using qRT-PCR from the plasma of mice injected subcutaneously with indicated breast-cancer cell lines as shown in Figure S3, and normalized to
miR-22, a microRNA of murine blood, but not found in the conditioned media of these cancer cell lines. B. Plot of quantities for indicated miRNAs in 3
samples each of human milk (milk), cell-free ductal lavages of breast cancer patients (lavages), extracellular (MCF7 X) and intracellular MCF7 (MCF7 C)
preparations, as quantitated by the stem-loop-primer qRT-PCR approach. A: lavages of a patient with atypical ductal hyperplasia; B and C: lavages of
patients with less severe epithelial hyperplasia. Inset: plot of ratios for miR-451 and miR-720. Dot shadings correspond to the same samples as labeled
in Figure 6B. C. Additional miRNAs quantified in ductal lavages using the linker-ligation qRT-PCR method.
doi:10.1371/journal.pone.0013515.g006
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All animals were handled in strict accordance with good animal
practices as defined by the RFUMS IACUC and accredited by the
Association for Assessment and Accreditation of Lab Animal Care
International (AAALAC) in compliance with the US Public Health
Service policy as assured by the Office of Laboratory Animal
Welfare. All animal work was approved by the RFUMS IACUC
under protocol 08-25.
Cell Culture
MDA-MB-231, MCF7, MCF 10A, BT-20, IMR90, SK-BR-3
cell lines were purchased from ATCC and maintained according
to provider’s recommendations, except for MCF 10A, and SK-
BR-3 cells. MCF 10A cells were maintained in media containing
horse serum as previously described [99]. However, for dot-blot
analyses, MCF 10As were grown in calf serum (CS), because
horse serum produced a high background reactivity with the
secondary antibody. For miRNA analyses, as a rule, MCF10A
cells were grown in FBS (Mediatech, Manassas, VA; Gemini,
West Sacramento, CA, or HyClone, Thermo Scientific, Pitts-
burgh, PA), because CS (Gemini, West Sacramento, CA)
contained some of the miRNAs measured (Figure S4A).
Microvesicles including exosomes were depleted from animal
sera by filtration and ultracentrifugation approaches as described
[23]. Alternatively, most miRNAs tested, including miR-451
were nearly undetectable in the FBS serum we used, consistent
with the fact that miR-451 has not been detected in blood
microvesicles [34] (Figure S4). SK-BR-3 cells were grown in
MEM supplemented with 10% FBS, NEAA and sodium
pyruvate.
Cells were grown in one 10 cm plate for routine miRNA
analyses and 10 15 cm plates for array analyses (2–50*106 cells) for
collection of conditioned supernatant and cell pellet. Depending
on the cell line used, media was replaced when cells were about
40–70% confluent, and maintained in this medium for 5 days to
collect the released particles and miRNAs, unless otherwise
indicated. Culturing for 5 days was used to effect optimal exosome
accumulation in the media [23]. On the fifth day cells were nearly
90% confluent. Cell viability was quantified using trypan blue as
described [100].
Mice
Nude mice (Taconic, Hudson, NY) were housed, maintained,
and injected with indicated breast cancer cell lines according to
RFUMS IACUC guidelines, and as described [101]. In brief, 5
million cells of indicated cell lines were injected in 100 ml BD
Matrigel (BD Biosciences, San Jose, California) into the right flank
of mice, and monitored for tumor growth. Mandibular blood was
drawn about weekly according to IACUC protocol and plasma
was prepared immediately or after refrigeration.
Lavages
Coded human breast ductal lavages were collected and
provided by Dr. David Danforth (NIH) in accordance to NIH/
NCI Institutional Review Board (IRB) guidelines, and were
described in [80].
Milk
Milk was donated from the Mother’s Milk Bank of Iowa (The
University of Iowa Children’s Hospital) and the Indiana Mother’s
Milk Bank, Inc. Eight hundred microliters of milk from three
mothers each was analyzed to determine miRNA composition.
The study was approved by the IRB of RFUMS (IRB protocol
number # 001 PATH).
Exosome Preparation
P70 and S70 was prepared as described [23]. In brief,
conditioned media or sera were cleared of cells and cell debris
by low-speed centrifugation and filtration, followed by concen-
trating the remaining particulate at 70,000 g for 1 h. The pellet
was washed in PBS by resuspension, and centrifuged again at
70,000 g. We chose this centrifugation speed over conventional
higher speed-preparations [102], because vesicles prepared at
higher speeds can lose some of their biological activities [23].
Negative-Stain EM
EM was done as described [23]. In brief, a P70 was fixed in
suspension with 2% PFA and 0.2% glutaraldehyde followed by
pelleting. This preparation was adsorbed to butvar-coated grids
followed by negative staining/embedding in 1% aqueous uranyl
acetate in 1% methyl cellulose [103]. Micrographs were acquired
using a transmission electron microscope (H7000T; Hitachi).
Dot-Blots and Slot-Blots
Blots were prepared using antibodies as described [23]. In brief,
P70s and other preparations were resuspended in Tris-buffered saline
and blotted onto Immobilon FL (Millipore) or nitrocellulose (What-
man) using a Bio-Dot Filtration Apparatus (BioRad). Antibody
binding was quantified using a Typhoon 9400 (GE Healthcare), and
goat-anti-mouse IgG-Alexa 488 (Invitrogen) and ImageQuant T
software. Antigenicity was determined by quantifying antibodies
bound to slot-or dot blotted P70 and other material using a standard
curve produced using dilutions of a known amount of primary
antibody.
RNA Extraction
Total RNA was extracted using Trizol procedure (Invitrogen).
For linker ligation qRT-PCR, small RNAs were enriched from
Trizol-extracted total RNA using PureLink (Invitrogen) according
to manufacturer’s instructions. For looped-primer qRT-PCR, total
RNA was extracted using Trizol.
59 End Labeling of RNA
RNA (,50 pmol) was isolated from MCF7 cells or exosomes
and enriched for small RNAs using PureLink followed by
treatment with with Antarctic phosphatase (NEB) according to
manufacturers protocol. Dephosphorylated RNA was 59 end
labeled using T4 polynucleotide kinase (-39 phosphatase minus)
(NEB) and 32P-c-ATP according to the manufacturers instruc-
tions. Radiolabeled RNA was separated on a 12% urea-
polyacrylamide gel.
miRNA Microarrays
MicroRNAs were screened by LC Sciences. One microgram of
MCF7 cellular RNA preparation was labeled with Cy5, and one
microgram of the extracellular RNA samples was labeled with
Cy3. In brief, the RNA was labeled with Cy5 or Cy3 and
hybridized to LCSciences standard arrays for mature miRNA of
all species available in the Sanger miRBase database (Release
12.0). The data were analyzed including background subtraction,
using a LOWESS (locally weighted regression) method on the
background-subtracted data. Only transcripts with a signal
intensity higher than 36 (background SD) and spot CV,0.5.
CV was calculated by (SD)/(signal intensity), and in which
repeating probes on the array produced signals from at least 50%
of the repeating probes are above detection level. Only data are
plotted in which extracellular or the cellular signal intensity for a
particular transcript was at least 100. Array data have been
Selective Release of MicroRNAs
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13515
submitted to the NCBI/GEO database, GPL10517 - LC_MRA-
1001_miRHuman_12.0_080901, GSE22235.
miRNA Quantitation
Two PCR approaches were used, stem-loop primers, which in
general are more sensitive and specific, and linker-ligated primers,
which allow sequencing of the 39 portion of miRNAs, and the
quantitation of a wider variety of miRNAs from the same cDNA
sample.
RNA Ligation
For linker-ligated qRT-PCR, the 39 end of RNA was ligated to
linker 1 (IDT, Coralville, IA) according to manufacturer
instructions for miRCat (IDT), except for the substitution of
Ligation Enhancer with PVA, and truncated RNA ligase 2 (NEB)
to promote polar ligation.
Reverse-Transcription
Reverse Transcription (RT) was carried out using SuperScript
III (Invitrogen) according to manufacturer’s instructions, and using
half of the total RNA or microRNA isolated from the P70, cells, or
other sources and using 20 pmoles of the primers discussed below.
For linker ligation, Modban primer [38] was used for reverse
transcription. For reverse transcription of mature miRNAs, we
used sets of stem-looped primers (Table S5). For pre-miRNAs
and other immature miRNAs, we used a set of primers specific for
the 39 end of immature miRNAs (Table S6), many of which are
described in [39].
Quantitative PCR
qPCR was performed on a 1/1000 dilution of the cDNA using
the primers listed inTables S5 and S6. The optimal concentration
of template used was determined empirically (Figure S5). qPCR
was performed in triplicate 20 ml reactions using an ABI 7500 Real-
Time PCR System (Applied Biosystems, Carlsbad, CA). The
reagents used included PCR primers produced by IDT, Invitrogen
or Operon and Power SYBR Green PCR Master Mix. We
optimized the qRT-PCR approach empirically to produce a single
band of the correct size by native PAGE (Figure 2E). In so doing,
we were able to confirm the specificity and purity of our amplified
and quantitated products. Quantitation was performed for up to 40
cycles of melting at 95uC for 15 s, annealing at 50uC for 1 min, and
extension at 73uC for 15 s, the optimal conditions determined
empirically. Standard PCR was performed on a MultiGene
Thermal Cycler (Labnet International, Inc, Edison, NJ) using
PCR with GoTaq polymerase (Promega).
Absolute Quantification
MiRNA abundance was measured by computing attomoles
based on comparing CT values of samples to dilutions of a
synthetic cDNA of the same miRNA sequence to make a standard
curve.
Relative Quantification
Relative quantification was performed using the ABI 7500
detection software with correction for amplification efficiency
based on an exponential model of PCR [104,105], and after
normalizing miRNA recovery to spiked control RNA (INT-RNA)
of known quantity (Table S4).
Quantitation of Pre-miRNA Sequences
Quantitation of pre-miRNA sequences was performed with the
primers listed in Table S6. To confirm pre-miRNA sequences
analyzed, we sequenced the PCR products (Table S7). To
determine proper processing of the pre-miRNAs, we designed two
upstream primers (US1 and US2) to the region 59 of the stem-
loops of the pri-miRNAs, and a downstream primer to the 39 end
of the immature miRNAs (Rm) for amplification by PCR. (Table
S6). The resulting products of expected size were sequenced to
confirm their identity (Table S7).
PAGE
Final PCR products were separated on a 12% native acrylamide
gel at room temperature, stained with SYBR Gold (Invitrogen),
and photographed using Gene Genius Bioimaging System, and
GeneSnap software (Syngene, Frederick, MD).
Cloning and Sequencing
PCR products were cloned into pGEM-T Easy (Promega,
Madison, WI) and sequenced at the DNA sequencing facility of
the University of Chicago Cancer Research Center. By sequencing
the stem-loop and linker-ligation products, we determined that
miR-100 identified by the array (Figure 2A) was in fact miR-99a,
which differs from miR-100 by a single nucleotide (Table S5).
Supporting Information
Figure S1 Some Diagnostic miRNAs are Mostly Retained.
Indicated miRNAs were amplified from RNA collected from cells
and the conditioned media of MCF7 cells using looped primers,
and separated by native PAGE. A miRNAs in which the cellular
(c), but not the extracellular (x) RNA population contained the
indicated miRNAs. In each case of the cellular sample, the main
band (arrow) was excised, cloned and sequenced and found to be
the expected amplified product. In the case of extracellular
samples the main bands, all of which migrated differently (star),
had no resemblance to the miRNA to be amplified as determined
by sequencing. B miRNAs in which the released miRNA
population contained a band of much lower abundance than the
retained population.
Found at: doi:10.1371/journal.pone.0013515.s001 (0.31 MB
PDF)
Figure S2 Lack of Correlation between Primary Transcript and
Release Rate of MiRNAs. Released/retained miRNAs (x/c) as
evaluated in Figure 1 are plotted according to chromosomal
location (chromosomes 1-X) from top to bottom. Micro-RNA
clusters are indicated in color. Note that for cluster miR-200c-141,
which is located in a single intron, 30 times more of its encoded
miR-200c molecules than miR-141 molecules were released from
cells (Figure 2A) than retained, indicating that the extent of
miRNA release is not determined at the primary-miRNA level. In
support of this idea, within the other miR-200 cluster, which
encodes miR-200a, miR-200b and miR-429 (Bracken CP,
Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF,
Goodall GJ. A doublenegative feedback loop between ZEB1-SIP1
and the microRNA-200 family regulates epithelialmesenchymal
transition. Cancer Res. 2008 Oct 1;68(19):7846–54), more than
half of miR-429 and miR-200b molecules are released, whereas
most of miR-200a is retained. Therefore, the extracellular
accumulation of mature miRNAs is regulated at levels other than
the primary transcript abundance. MicroRNAs contained in
particular clusters are indicated by red or green colored bars.
Found at: doi:10.1371/journal.pone.0013515.s002 (2.32 MB
PDF)
Figure S3 MiR-1246 is a Reliable Indicator of Body Fluids
Conditioned by Mammary Epithelia. A tumor growth of
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xenografted cells of mice used for assessment of miRNA
abundance in blood plasma as indicated in Figure 4A. The tumor
size is presented as the product of the 3 diameters. Data presented
in Figure 6 are from bleeds at day 30 (arrow). B PAGE of end-
point PCR of miR-1246 of bleeds of MCF7-1 and MDA-MB-231.
Found at: doi:10.1371/journal.pone.0013515.s003 (0.20 MB
PDF)
Figure S4 Fetal Bovine Serum Does Not Interfere With
Extracellular MiRNA Assessment. A Relative abundance of
indicated miRNAs in calf serum (CS) and fetal bovine serum
(FBS), normalized to INT-RNA. Note the absence of miR-451
from FBS, but that CS contains measurable levels of Bos taurus
miR-451, which differs from hsa-miR-451 by a single terminal
nucleotide (Long JE, Chen HX. Identification and characteristics
of cattle microRNAs by homology searching and small RNA
cloning. Biochem Genet. 2009 Jun;47(5–6):329–43). B End-point
PCR using stem-loop primers on extracellular (x) and cellular (c)
miR-451 of indicated breast cancer cell lines grown in complete
FBS, or in FBS depleted of microvesicles (FBS S100). C Ratio of
miRNAs in c and x of cells grown in complete FBS and FBS
depleted of microvesicles (FBS S100). D. MiRNAs measured as in
Supplemental Figure S4C, by qRT-PCR using linker-ligation.
Error bars indicate standard deviation. A is an average of 2
experiments, C and E are averages of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0013515.s004 (1.28 MB
PDF)
Figure S5 Template-independent amplification products at low
template concentrations. Mature miR-16 was assessed by the
stem-loop-primer protocol on 5 fold serial dilutions of a synthetic
DNA construct reflecting the expected product of miR-16.
Found at: doi:10.1371/journal.pone.0013515.s005 (0.22 MB
PDF)
Table S1 RRNA and snRNA fragments detected in unique
RNA band of extracellular miRNAs. RNA sequences cloned and
sequenced from bands in Figure 1, D and E, marked with a star.
Found at: doi:10.1371/journal.pone.0013515.s006 (0.03 MB
DOC)
Table S2 RNA Subpopulation Enriched in the Extracellular
Space. Sequences identified with D1, D2, D3 represent sequence
data of miRNAs extracted from cells, all others are miRNA
sequences retrieved from the extracellular space.
Found at: doi:10.1371/journal.pone.0013515.s007 (0.05 MB
DOC)
Table S3 Oligonucleotides used for Mature miRNA Quantita-
tion.
Found at: doi:10.1371/journal.pone.0013515.s008 (0.07 MB
DOC)
Table S4 Stem Looped Primers used for Simultaneous Analyses
of Multiple Transcripts.
Found at: doi:10.1371/journal.pone.0013515.s009 (0.05 MB
DOC)
Table S5 Confirmed sequences of qPCR products quantified
using linker ligated primers.
Found at: doi:10.1371/journal.pone.0013515.s010 (0.03 MB
DOC)
Table S6 Primers for Quantifying pre-miRNAs and Other
Immature miRNAs.
Found at: doi:10.1371/journal.pone.0013515.s011 (0.07 MB
DOC)
Table S7 Sequences of Immature miRNAs Detected.
Found at: doi:10.1371/journal.pone.0013515.s012 (0.05 MB
DOC)
Acknowledgments
We thank the women who donated human milk to the Mother’s Milk Bank
of Iowa (The University of Iowa Children’s Hospital) and the Indiana
Mother’s Milk Bank, Inc. We thank Carl Correll, Judy Potashkin and
Mallory Havens, Sarah Linnstaedt and Yuri Lazebnik for productive
discussions and critical review of the manuscript.
Author Contributions
Conceived and designed the experiments: MLH DMD. Performed the
experiments: LP SCSY RI DJK SAH MLH DMD. Analyzed the data: LP
SCSY RI DJK SAH DNDJ MLH DMD. Contributed reagents/materials/
analysis tools: DNDJ. Wrote the paper: DMD.
References
1. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA
gene expression deregulation in human breast cancer. Cancer Res 65:
7065–7070.
2. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and
metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682–688.
3. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, et al. (2008) The
microRNAs miR-373 and miR-520c promote tumour invasion and metastasis.
Nat Cell Biol 10: 202–210.
4. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. (2009) A
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.
Cell 137: 1032–1046.
5. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. (2008)
Endogenous human microRNAs that suppress breast cancer metastasis. Nature
451: 147–152.
6. Si ML, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor
growth. Oncogene 26: 2799–2803.
7. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor
suppressor genes in invasion and metastasis. Cell Res 18: 350–359.
8. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, et al. (2008)
Programmed cell death 4 (PDCD4) is an important functional target of the
microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026–1033.
9. Hossain A, Kuo MT, Saunders GF (2006) Mir-17-5p regulates breast cancer
cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26:
8191–8201.
10. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007)
MicroRNA expression profiling of human breast cancer identifies new markers
of tumor subtype. Genome Biol 8: R214.
11. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008)
Detection of elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672–675.
12. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res 18: 997–1006.
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection.
Proc Natl Acad Sci U S A 105: 10513–10518.
14. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, et al. (2009) Detection
of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:
e6229.
15. Zhu W, Qin W, Atasoy U, Sauter ER (2009) Circulating microRNAs in breast
cancer and healthy subjects. BMC Res Notes 2: 89.
16. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ (2009)
MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009: 950201.
17. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010)
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast
Cancer. Ann Surg 251: 499–505.
18. Huang Z, Huang D, Ni S, Peng Z, ShengW, et al. (2009) PlasmamicroRNAs are
promising novel biomarkers for early detection of colorectal cancer. Int J Cancer.
19. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:
13–21.
20. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009)
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer
10: 42–46.
Selective Release of MicroRNAs
PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e13515
21. Go AT, Visser A, van Dijk M, Mulders MA, Eijk P, et al. (2008) A novel
method to identify syncytiotrophoblast-derived RNA products representative of
trisomy 21 placental RNA in maternal plasma. Methods Mol Biol 444:
291–302.
22. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, et al. (2006) Embryonic
stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence
for horizontal transfer of mRNA and protein delivery. Leukemia 20: 847–856.
23. Duelli DM, Hearn S, Myers MP, Lazebnik Y (2005) A primate virus generates
transformed human cells by fusion. J Cell Biol 171: 493–503.
24. Coren LV, Shatzer T, Ott DE (2008) CD45 immunoaffinity depletion of
vesicles from Jurkat T cells demonstrates that ‘‘exosomes’’ contain CD45: no
evidence for a distinct exosome/HIV-1 budding pathway. Retrovirology 5: 64.
25. Booth AM, Fang Y, Fallon JK, Yang JM, Hildreth JE, et al. (2006) Exosomes
and HIV Gag bud from endosome-like domains of the T cell plasma
membrane. J Cell Biol 172: 923–935.
26. Gould SJ, Booth AM, Hildreth JE (2003) The Trojan exosome hypothesis. Proc
Natl Acad Sci U S A 100: 10592–10597.
27. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic
exchange between cells. Nat Cell Biol 9: 654–659.
28. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, et al. Functional delivery of viral miRNAs via exosomes. Proc
Natl Acad Sci U S A 107: 6328–6333.
29. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, et al. (2009) Mesenchymal
stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids
Res 38: 215–224.
30. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008)
Glioblastoma microvesicles transport RNA and proteins that promote tumour
growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470–1476.
31. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010)
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living
Cells. J Biol Chem 285: 17442–17452.
32. Lee YS, Pressman S, Andress AP, Kim K, White JL, et al. (2009) Silencing by
small RNAs is linked to endosomal trafficking. Nat Cell Biol 11: 1150–1156.
33. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, et al. (2009)
Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent
vascular protection. Sci Signal 2: ra81.
34. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of
microRNA expression in human peripheral blood microvesicles. PLoS ONE 3:
e3694.
35. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, et al. (2008) Detection
and characterization of placental microRNAs in maternal plasma. Clin Chem
54: 482–490.
36. Staubach S, Razawi H, Hanisch FG (2009) Proteomics of MUC1-containing
lipid rafts from plasma membranes and exosomes of human breast carcinoma
cells MCF-7. Proteomics 9: 2820–2835.
37. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, et al. (2009)
Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis.
38. Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny
RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294:
858–862.
39. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, et al. (2008) Real-time PCR
quantification of precursor and mature microRNA. Methods 44: 31–38.
40. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009)
Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal
Stem Cells. Cell 138: 592–603.
41. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The
miR-200 family and miR-205 regulate epithelial to mesenchymal transition by
targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601.
42. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in
quantitative RT-PCR assays: identification of suitable reference RNA targets in
normal and cancerous human solid tissues. RNA 14: 844–852.
43. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, et al. (2009)
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase
6 expression in pancreatic cancer. Pancreatology 9: 293–301.
44. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal
and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
45. Bussing I, Slack FJ, Grosshans H (2008) let-7 microRNAs in development, stem
cells and cancer. Trends Mol Med 14: 400–409.
46. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, et al. (2010)
Comprehensive MicroRNA profiling for head and neck squamous cell
carcinomas. Clin Cancer Res 16: 1129–1139.
47. Yu X, Riley T, Levine AJ (2009) The regulation of the endosomal
compartment by p53 the tumor suppressor gene. FEBS J 276: 2201–2212.
48. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N (2008) Identification
of suitable endogenous control genes for microRNA gene expression analysis in
human breast cancer. BMC Mol Biol 9: 76.
49. Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN (2009) Myc-regulated
microRNAs attenuate embryonic stem cell differentiation. EMBO J 28:
3157–3170.
50. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA
signatures in human ovarian cancer. Cancer Res 67: 8699–8707.
51. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ (2007) A
role for microRNAs in maintenance of mouse mammary epithelial progenitor
cells. Genes Dev 21: 3238–3243.
52. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, et al. (2008)
Detailed characterization of a homozygously deleted region corresponding to a
candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes
Chromosomes Cancer 47: 810–818.
53. Ohgaki K, Iida A, Kasumi F, Sakamoto G, Akimoto M, et al. (1998) Mapping
of a new target region of allelic loss to a 6-cM interval at 21q21 in primary
breast cancers. Genes Chromosomes Cancer 23: 244–247.
54. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, et al. (2009) Robust global
micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer
tissues. Lab Invest 89: 597–606.
55. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, et al. (2008) hsa-miR-210
Is induced by hypoxia and is an independent prognostic factor in breast cancer.
Clin Cancer Res 14: 1340–1348.
56. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family
determines the epithelial phenotype of cancer cells by targeting the E-cadherin
repressors ZEB1 and ZEB2. Genes Dev 22: 894–907.
57. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, et al. (2008) A
double-negative feedback loop between ZEB1-SIP1 and the microRNA-200
family regulates epithelial-mesenchymal transition. Cancer Res 68: 7846–7854.
58. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, et al.
(2008) A microRNA DNA methylation signature for human cancer metastasis.
Proc Natl Acad Sci U S A 105: 13556–13561.
59. Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of
human miRNAs and indications for an involvement of miRNA in cell growth
and apoptosis. Nucleic Acids Res 33: 1290–1297.
60. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, et al. (2007)
MicroRNA gene expression during retinoic acid-induced differentiation of
human acute promyelocytic leukemia. Oncogene 26: 4148–4157.
61. Itoh T, Nozawa Y, Akao Y (2009) MicroRNA-141 and -200a are involved in
bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by
targeting distal-less homeobox 5. J Biol Chem 284: 19272–19279.
62. Wilfred BR, Wang WX, Nelson PT (2007) Energizing miRNA research: a
review of the role of miRNAs in lipid metabolism, with a prediction that miR-
103/107 regulates human metabolic pathways. Mol Genet Metab 91: 209–217.
63. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O (2009) Multivesicular bodies
associate with components of miRNA effector complexes and modulate
miRNA activity. Nat Cell Biol 11: 1143–1149.
64. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222
negatively regulates estrogen receptor alpha and is associated with tamoxifen
resistance in breast cancer. J Biol Chem 283: 31079–31086.
65. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008)
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting
p27Kip1. J Biol Chem 283: 29897–29903.
66. Kawahara Y, Zinshteyn B, Chendrimada TP, Shiekhattar R, Nishikura K
(2007) RNA editing of the microRNA-151 precursor blocks cleavage by the
Dicer-TRBP complex. EMBO Rep 8: 763–769.
67. Helvik SA, Snove O, Jr., Saetrom P (2007) Reliable prediction of Drosha
processing sites improves microRNA gene prediction. Bioinformatics 23:
142–149.
68. Luciano DJ, Mirsky H, Vendetti NJ, Maas S (2004) RNA editing of a miRNA
precursor. RNA 10: 1174–1177.
69. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, et al. (2006)
Modulation of microRNA processing and expression through RNA editing by
ADAR deaminases. Nat Struct Mol Biol 13: 13–21.
70. Cochrane DR, Howe EN, Spoelstra NS, Richer JK (2010) Loss of miR-200c: A
Marker of Aggressiveness and Chemoresistance in Female Reproductive
Cancers. J Oncol 2010: 821717.
71. Qian S, Ding JY, Xie R, An JH, Ao XJ, et al. (2008) MicroRNA expression
profile of bronchioalveolar stem cells from mouse lung. Biochem Biophys Res
Commun 377: 668–673.
72. Williams AE, Perry MM, Moschos SA, Lindsay MA (2007) microRNA
expression in the aging mouse lung. BMC Genomics 8: 172.
73. Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, et al. (2009)
MicroRNA-338-3p and microRNA-451 contribute to the formation of
basolateral polarity in epithelial cells. Nucleic Acids Res 37: 3821–3827.
74. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, et al. (2009) microRNA-451
regulates macrophage migration inhibitory factor production and proliferation
of gastrointestinal cancer cells. Clin Cancer Res 15: 2281–2290.
75. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, et al. (2008) MIR-451
and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.
Biochem Biophys Res Commun 376: 86–90.
76. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. (2008)
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells
to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152–2159.
77. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007)
Altered MicroRNA expression confined to specific epithelial cell subpopula-
tions in breast cancer. Cancer Res 67: 11612–11620.
78. Admyre C, Johansson SM, Qazi KR, Filen JJ, Lahesmaa R, et al. (2007)
Exosomes with immune modulatory features are present in human breast milk.
J Immunol 179: 1969–1978.
Selective Release of MicroRNAs
PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e13515
79. Kosaka N, Izumi H, Sekine K, Ochiya T (2010) microRNA as a new immune-
regulatory agent in breast milk. Silence 1: 7.
80. Danforth DN, Jr., Abati A, Filie A, Prindiville SA, Palmieri D, et al. (2006)
Combined breast ductal lavage and ductal endoscopy for the evaluation of the
high-risk breast: a feasibility study. J Surg Oncol 94: 555–564.
81. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, et al. (2010)
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to
metabolic stress in glioma cells. Mol Cell 37: 620–632.
82. Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, et al.
(1995) Identification of four novel human genes amplified and overexpressed in
breast carcinoma and localized to the q11-q21.3 region of chromosome 17.
Genomics 28: 367–376.
83. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, et al. (2002)
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic
cancer. Genes Chromosomes Cancer 35: 353–358.
84. Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, et al. (2002) Targets of
gene amplification and overexpression at 17q in gastric cancer. Cancer Res 62:
2625–2629.
85. Fevrier B, Raposo G (2004) Exosomes: endosomal-derived vesicles shipping
extracellular messages. Curr Opin Cell Biol 16: 415–421.
86. Duelli D, Lazebnik Y (2007) Cell-to-cell fusion as a link between viruses and
cancer. Nat Rev Cancer 7: 968–976.
87. Jackson DB (2009) Serum-based microRNAs: are we blinded by potential? Proc
Natl Acad Sci U S A 106: E5.
88. Heaphy CM, Griffith JK, Bisoffi M (2009) Mammary field cancerization:
molecular evidence and clinical importance. Breast Cancer Res Treat 118:
229–239.
89. Johnstone RM, Mathew A, Mason AB, Teng K (1991) Exosome formation
during maturation of mammalian and avian reticulocytes: evidence that
exosome release is a major route for externalization of obsolete membrane
proteins. J Cell Physiol 147: 27–36.
90. Lee YS, Shibata Y, Malhotra A, Dutta A (2009) A novel class of small RNAs:
tRNA-derived RNA fragments (tRFs). Genes Dev 23: 2639–2649.
91. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, et al. (2010) A Novel
miRNA Processing Pathway Independent of Dicer Requires Argonaute2
Catalytic Activity. Science 328: 1694–1698.
92. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, et al. (2001)
Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential
for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17:
301–307.
93. Lang JE, Kuerer HM (2007) Breast ductal secretions: clinical features, potential
uses, and possible applications. Cancer Control 14: 350–359.
94. Dua RS, Isacke CM, Gui GP (2006) The intraductal approach to breast cancer
biomarker discovery. J Clin Oncol 24: 1209–1216.
95. Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, et al. (2009) Ductal lavage is
an inefficient method of biomarker measurement in high-risk women. Cancer
Prev Res (Phila Pa) 2: 265–273.
96. Loud JT, Thiebaut AC, Abati AD, Filie AC, Nichols K, et al. (2009) Ductal
lavage in women from BRCA1/2 families: is there a future for ductal lavage in
women at increased genetic risk of breast cancer? Cancer Epidemiol
Biomarkers Prev 18: 1243–1251.
97. Hata T, Murakami K, Nakatani H, Yamamoto Y, Matsuda T, et al. (2010)
Isolation of bovine milk-derived microvesicles carrying mRNAs and micro-
RNAs. Biochem Biophys Res Commun.
98. Welsch U, Oppermann T, Mortezza M, Hofter E, Unterberger P (2007)
Secretory phenomena in the non-lactating human mammary gland. Ann Anat
189: 131–141.
99. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and
oncogenesis of MCF-10A mammary epithelial acini grown in three-
dimensional basement membrane cultures. Methods 30: 256–268.
100. Duelli DM, Lazebnik YA (2000) Primary cells suppress oncogene-dependent
apoptosis. Nat Cell Biol 2: 859–862.
101. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, et al. (2007)
A virus causes cancer by inducing massive chromosomal instability through cell
fusion. Curr Biol 17: 431–437.
102. Mathias RA, Lim JW, Ji H, Simpson RJ (2009) Isolation of extracellular
membranous vesicles for proteomic analysis. Methods Mol Biol 528: 227–242.
103. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, et al.
(1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:
1161–1172.
104. Liu W, Saint DA (2002) A new quantitative method of real time reverse
transcription polymerase chain reaction assay based on simulation of
polymerase chain reaction kinetics. Anal Biochem 302: 52–59.
105. Cikos S, Bukovska A, Koppel J (2007) Relative quantification of mRNA:
comparison of methods currently used for real-time PCR data analysis. BMC
Mol Biol 8: 113.
Selective Release of MicroRNAs
PLoS ONE | www.plosone.org 13 October 2010 | Volume 5 | Issue 10 | e13515
